In Brief: GATT patent extensions
Executive Summary
GATT patent extensions: Merck v. Kessler patent ruling upheld Jan. 21 when U.S. Supreme Court lets stand D.C. appeals court ruling in case. The D.C. three judge panel ruled in April that Waxman/Hatch extensions may be added to the 20-years-from-filing patent term established under the General Agreement on Tariffs & Trade if the original 17-year term of the patent was in force at the time GATT took effect on June 8, 1995. However, the panel ruled that an extension may not be added if the patent was in force due to Waxman/Hatch extensions ("The Pink Sheet" April 15, 1996, T&G-1)...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth